Press Releases

NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS
April 28, 2009 15:00 (CEST)
Active Biotech presents S100A9 as a target for quinoline compounds
April 28, 2009 08:30 (CEST)
Active Biotech AB Interim report January-March 2009
April 23, 2009 08:30 (CEST)
Annual Report 2008 Active Biotech AB (publ)
April 6, 2009 08:32 (CEST)
The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M
April 6, 2009 08:31 (CEST)
Notice of Annual General Meeting of Shareholders
April 6, 2009 08:30 (CEST)
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA
February 12, 2009 17:28 (CET)
Active Biotech AB year End Report January-December 2008
February 12, 2009 08:30 (CET)
Information from Active Biotech AB's Election Committee
January 26, 2009 10:30 (CET)
Active Biotech's Cancer Project ANYARA: Combination with Established Tumor Therapies Promising
December 10, 2008 08:30 (CET)